Key stats
About ARK Genomic Revolution ETF
Expense ratio
0.75%
Home page
Inception date
Oct 31, 2014
ARKG reaches across multiple sectors and geographies for companies that the advisor believes will benefit from innovations in the genomics-related industry. Such companies are those that may develop, produce or enable targeted therapeutics, bioinformatics, stem cells or molecular diagnostics. The reality is almost all of its holdings are in US healthcare-related companies, with biotech naturally leading the way. This is a niche fund which employs an actively-managed strategy, hence investors should look closely at where the fund makes its bets before investing.
Classification
What's in the fund
Exposure type
Health Technology
Technology Services
Stock breakdown by region
Displays a symbol's price movements over previous years to identify recurring trends.